Comparative Pharmacology
Head-to-head clinical analysis: NIKKI versus SEASONALE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIKKI versus SEASONALE.
NIKKI vs SEASONALE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NIKKI is a combination oral contraceptive containing ethinyl estradiol and drospirenone. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropin release, thereby inhibiting ovulation.
Seasonale is a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. It suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus to reduce sperm penetration and endometrial lining to reduce implantation.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel) orally once daily for 84 consecutive days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinical context: allows once-daily dosing; steady-state reached in ~3 days
Ethinyl estradiol: terminal half-life 13-27 hours (mean 17 hours); levonorgestrel: terminal half-life 11-45 hours (mean 25 hours). Clinical context: Supports once-daily dosing; steady-state achieved within 5-10 days.
Renal: 50% (20% unchanged, 30% as metabolites); Fecal: 40%; Biliary: 10%
Renal excretion of metabolites (approximately 50-60% as glucuronide and sulfate conjugates of ethinyl estradiol and levonorgestrel) and fecal elimination (approximately 40-50%).
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal